TR201719926A2 - Farmasöti̇k olarak kabul edi̇lebi̇li̇r li̇tyum tuzlari ve c vi̇tami̇ni̇ i̇çeren farmasöti̇k bi̇leşi̇mler - Google Patents

Farmasöti̇k olarak kabul edi̇lebi̇li̇r li̇tyum tuzlari ve c vi̇tami̇ni̇ i̇çeren farmasöti̇k bi̇leşi̇mler Download PDF

Info

Publication number
TR201719926A2
TR201719926A2 TR2017/19926A TR201719926A TR201719926A2 TR 201719926 A2 TR201719926 A2 TR 201719926A2 TR 2017/19926 A TR2017/19926 A TR 2017/19926A TR 201719926 A TR201719926 A TR 201719926A TR 201719926 A2 TR201719926 A2 TR 201719926A2
Authority
TR
Turkey
Prior art keywords
vitamin
pharmaceutical compositions
compositions containing
pharmaceutically acceptable
lithium salts
Prior art date
Application number
TR2017/19926A
Other languages
English (en)
Inventor
Gencaslan Ibrahi̇m
Original Assignee
Ibrahim Gencaslan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ibrahim Gencaslan filed Critical Ibrahim Gencaslan
Priority to TR2017/19926A priority Critical patent/TR201719926A2/tr
Publication of TR201719926A2 publication Critical patent/TR201719926A2/tr

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Buluş lityum ve C vitaminini tek doz içerisinde birlikte içeren farmasötik kompozisyonlar ve bu kompozisyonların psikiyatrik hastalıklardan özellikle bipolar bozuklukların tedavisinde kullanımı ile ilgilidir.
TR2017/19926A 2017-12-08 2017-12-08 Farmasöti̇k olarak kabul edi̇lebi̇li̇r li̇tyum tuzlari ve c vi̇tami̇ni̇ i̇çeren farmasöti̇k bi̇leşi̇mler TR201719926A2 (tr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TR2017/19926A TR201719926A2 (tr) 2017-12-08 2017-12-08 Farmasöti̇k olarak kabul edi̇lebi̇li̇r li̇tyum tuzlari ve c vi̇tami̇ni̇ i̇çeren farmasöti̇k bi̇leşi̇mler

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/19926A TR201719926A2 (tr) 2017-12-08 2017-12-08 Farmasöti̇k olarak kabul edi̇lebi̇li̇r li̇tyum tuzlari ve c vi̇tami̇ni̇ i̇çeren farmasöti̇k bi̇leşi̇mler

Publications (1)

Publication Number Publication Date
TR201719926A2 true TR201719926A2 (tr) 2019-06-21

Family

ID=67952612

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/19926A TR201719926A2 (tr) 2017-12-08 2017-12-08 Farmasöti̇k olarak kabul edi̇lebi̇li̇r li̇tyum tuzlari ve c vi̇tami̇ni̇ i̇çeren farmasöti̇k bi̇leşi̇mler

Country Status (1)

Country Link
TR (1) TR201719926A2 (tr)

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
CY1125488T1 (el) Παραγωγα πυριδινης και θεραπευτικες χρησεις αυτων ως αναστολεις trpc6
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
CL2019002240A1 (es) Dendrímeros terapéuticos.
MX378566B (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
MX391392B (es) ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a.
MX2024002360A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
JOP20210090A1 (ar) مشتقات بيريدينيل سلفوناميد، تركيبات صيدلانية واستخداماتها
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
PH12021550671A1 (en) Prodrugs of cgrp antagonists
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
MX2019005309A (es) Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
ZA201906153B (en) Pharmaceutical compositions for combination therapy
TR201717703A2 (tr) Api̇ksaban formülasyonlari
TR201719926A2 (tr) Farmasöti̇k olarak kabul edi̇lebi̇li̇r li̇tyum tuzlari ve c vi̇tami̇ni̇ i̇çeren farmasöti̇k bi̇leşi̇mler
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
EA202190247A1 (ru) ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ